Pfizer Inc. said on May 10 the company will pay $11.6 billion to buy Biohaven Pharmaceutical Holding Co., making a big bet on its ability to boost sales of the top-selling pill in a new class of migraine drugs.
AbbVie got off to a strong start for 2022, driven by success from Skyrizi and Rinvoq, as well as the company’s neuroscience platform that includes the company’s depression treatments and its three-pronged approach to migraine.
Axsome Therapeutics said on April 25 the company expects the U.S. health regulator to decline approval for the drug developer’s treatment of acute migraine over unresolved issues of its quality control processes, sending shares of Axsome down 20 percent.
Biohaven Presentation at AAN Showed Decreased Opioid Use in Migraine Patients Following Nurtec® ODT Therapy: A Real-World Administrative Claims Analysis
Acute Migraine, Episodic Migraine, Hydrocodone, Migraine, Migraine Headaches, Opioid Dependence, Opioid Prescriptions, Opioid Safety, Prescriptions, R&D, Real world evidence, Research & Development, TherapeuticsLongitudinal medical and prescription claims were used to assess opioid prescriptions and MME’s dispensed amongst migraine patients nine months prior to and nine months following Nurtec® ODT initiation. Among […]
10 Biggest Novel Drug Approvals of 2021
Alzheimer's Disease, BNT162b2 (Pfizer and BioNTech), COVID-19 Vaccines, Cytomegalovirus Infections, Episodic Migraine, FDA, Lupus nephritis, New Drug Approvals, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer (NSCLC), Pfizer, Sickle Cell Disease, Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), Therapeutics, Weight managementBioSpace looks at the 10 biggest drug approvals of 2021, headlined by Biogen’s Aduhelm (aducanumab) for Alzheimer’s disease and Pfizer and BioNTech’s COVID-19 vaccine Comirnaty.
Eli Lilly and Company announced the launch of a head-to-head study to compare once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant) for the prevention of migraine.
The U.S. Food and Drug Administration approved Biohaven Pharmaceutical Holding Company Ltd.’s Nurtec ODT (rimegepant 75 mg) for the preventive treatment of migraine. Nurtec ODT is indicated for adult patients with episodic migraine, e.g. those who experience less than 15 headache days per month.
The U.S. Food and Drug Administration accepted AbbVie’s New Drug Application for atogepant, an investigational orally administered calcitonin gene-related peptide (CGRP) receptor antagonist for the preventive treatment of migraine in adults who meet criteria for episodic migraine.
The U.S. Food and Drug Administration accepted for review Impel NeuroPharma’s 5O5(b)(2) New Drug Application (NDA) for INP104 for the acute treatment of migraine headaches with or without aura in adults.
Biggest Novel Drug Approvals in 2020
"Bad" LDL Cholesterol, Acute Migraine, Antibodies, Coronavirus Disease (COVID-19) Pandemic, Coronavirus Disease 2019 (COVID-19), EvaluatePharma, FDA, Future Blockbusters, New Drug Approvals, Peanut Allergies, Relapsing Multiple Sclerosis (RMS), Spinal Muscular Atrophy (SMA), Therapeutics, Thyroid Eye Disease (TED), Triple Negative Breast Cancer (TNBC)BioSpace reviewed the top 10 novel drug approvals of 2020, loosely based on projected earnings in the upcoming years.